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Abstract: It can be argued that the arrival of the
‘‘genomics era’’ has significantly shifted the paradigm of
vaccine and therapeutics development from microbiolog-
ical to sequence-based approaches. Genome sequences
provide a previously unattainable route to investigate the
mechanisms that underpin pathogenesis. Genomics,
transcriptomics, metabolomics, structural genomics, pro-
teomics, and immunomics are being exploited to perfect
the identification of targets, to design new vaccines and
drugs, and to predict their effects in patients. Further-
more, human genomics and related studies are providing
insights into aspects of host biology that are important in
infectious disease. This ever-growing body of genomic
data and new genome-based approaches will play a
critical role in the future to enable timely development of
vaccines and therapeutics to control emerging infectious
diseases.
By controlling debilitating and often-lethal infectious diseases,
vaccines and antibiotics have had an enormous impact on world
health. Now, with the arrival of the ‘‘genomics era,’’ a paradigm
shift is occurring in the development of vaccines—and potentially
also in the development of antibiotics—that is providing fresh
impetus to this field. The world is still faced with a huge burden of
infection, however, by classic pathogens (e.g., typhoid, measles),
recently discovered causes of disease (e.g., Helicobacter pylori and
hepatitis C virus [HCV]), and emerging infectious diseases (EIDs,
e.g., H1N1 swine flu and severe acute respiratory syndrome
coronavirus [SARS-CoV]). In addition, variant forms of previ-
ously identified infectious diseases are reemerging (e.g., Streptococcus
pyogenes, also known as group A streptococcus [GAS], and dengue
fever), along with antibiotic-resistant forms of microbes (e.g.,
methicillin-resistant Staphylococcus aureus [MRSA] and Mycobacterium
tuberculosis) [1,2] (for a list of EIDs see http://www3.niaid.nih.gov/
topics/emerging/list.htm). The World Health Organization
(WHO) estimates that we can expect at least one such new
pathogen to appear every year.
The fact that an infectious disease has emerged or reemerged
indicates immune naı ¨vety in the infected population, or altered
virulence potential or an increase in antibiotic/antiviral resistance
in the pathogen population. The rapid development of vaccines
and therapeutics that target these pathogens is therefore essential
to limit their spread. Traditional empirical approaches that screen
for vaccines or drugs a few candidates at a time are time-
consuming and have often proven insufficient to control many
EIDs, particularly when the causative pathogens are antigenically
diverse (e.g., HIV), cannot be cultivated in the laboratory (e.g.,
HCV), lack suitable animal models of infection (e.g., Neisseria spp.),
have complex mechanisms of pathogenesis (e.g., retroviruses),
and/or are controlled by mucosal or T cell–dependent immune
responses rather than humoral immune responses (e.g., Shigella
spp., M. tuberculosis) [3]. For many EIDs, the wealth of information
emerging in the genome era has already had a significant impact
on the way we approach vaccine and therapeutic development.
For EIDs that appear in the near future, genomics will be in the
first line of defense in terms of antigen identification, diagnostic
development, and functional characterization.
Since the completion of the genome sequence of Haemophilus
influenzae—thefirstfinishedbacterialgenomesequence—in1995[4],
advances in sequencing technology and bioinformatics have
produced an exponential growth of genome sequence information.
At least one genome sequence is now available for each major
human pathogen.Asof October 2009, over 1,000 bacterial genomes
were ‘‘completed’’ (i.e., closed genomes and whole genome shotgun
sequences) and more than 1,000 were ongoing; over 3,000 viral
genomes were completed (http://www.genomesonline.org/gold.cgi,
http://www.ncbi.nlm.nih.gov/genomes/MICROBES/microbial_
taxtree.html, http://cmr.jcvi.org/tigr-scripts/CMR/shared/
Genomes.cgi). For a bacterial pathogen, which may have more
than 4,000 genes, the genome sequence provides the complete
genetic repertoire of antigens or drug targets from which novel
candidates can be identified. For viral pathogens that may possess
fewer than 10 genes, genomics can be used to define the variability
that may exist between isolates. Host genetic factors also play a role
in infectious disease [5,6], however, and the availability of
‘‘complete’’ human genome sequences, as well as large-scale human
genome projects (see http://www.1000genomes.org/), are valuable
resources.Hence,thesequencesofbothpathogenandhostgenomes
canfacilitate identificationof a growingnumberofpotential vaccine
and drug targets (Figure 1). It is estimated that 10–100 times more
candidates can be identified in one to two years using genomics-
based approaches than can be identified by conventional methods
in the same time frame. Furthermore, genomics-based vaccine
projectshavesubstantially increased ourunderstandingof microbial
physiology, epidemiology, pathogenesis, and protein functions (see
Box 1).
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PLoS Genetics | www.plosgenetics.org 1 October 2009 | Volume 5 | Issue 10 | e1000612Figure 1. Genomics-based approaches used in the control of EIDs from the outbreak of a disease to the development of a vaccine
or drug. (A) The causative agent of a disease may first be identified from patient samples by using metagenomics. (B) Vaccine and therapeutic
targets can be identified from the pathogen genome using a variety of screening approaches that focus on the genome, transcriptome, proteome,
immunome or structural genome. (C) The human genome can be screened to avoid homologies or similarities with pathogen vaccine and
therapeutic targets, or to identify new targets. (D) Once candidate vaccine and therapeutic targets have been identified they must be shown to
provide protection against disease and to be safe for use in patients. (E) The clinically tested vaccine or therapeutic can then be licensed for use. The
clinical responses of a vaccine and/or therapeutic can be analyzed using human genome based studies (dotted arrows). The pathogen genome can
also be used to analyze mutants that are able to evade the immune system in vaccinated subjects or organisms that develop antibiotic resistance.
Examples of the approaches indicated are given in Table 1.
doi:10.1371/journal.pgen.1000612.g001
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genetic material recovered directly from a sample) can be applied to
diseased human samples to aid the rapid identification of the
causative agent [7,8]. Once the complete genome sequence of the
organism is available, high-throughput approaches can be used to
screen for target molecules, as outlined below and in Table 1 [9,10].
Screening approaches vary depending on the nature of the pathogen
but are based on several accepted principles and key requirements of
vaccines and therapeutics, including the need for targets to be (i)
expressed and accessible to the host immune system, or to a
therapeutic agent, during human disease; (ii) genetically conserved;
(iii) important for survival or pathogenesis; and (iv) free of measurable
homology or similarity to host factors. Although many of the
approaches described here focus on vaccine development, which
involves screening of candidates for immunogenicity, they are largely
applicable to drug development by altering the selection criteria used
and screening candidates against compound libraries [11–13].
Reverse Vaccinology, Pan-genomics, and
Comparative Genomics
The idea behind reverse vaccinology is to screen an entire
pathogen genome to find genes that encode proteins with the
attributes of good vaccine targets, such as, for example, bacterial
surface associated proteins [14]. These proteins can then undergo
normal laboratory evaluation for immunogenicity. The Neisseria
meningitidis serogroup B (MenB) reverse vaccinology project provides
the ‘‘proof of concept’’ for this type of approach. This project
identified more novel vaccine candidates in 18 months than had
been discovered in 40 years of conventional vaccinology [15].
Analysis of the genome sequence of the virulent MenB strain MC58
found 2,158 predicted open reading frames (ORFs); these were
screened using bioinformatics tools to identify 570 ORFs that were
predicted to encode surface-exposed or secreted proteins that might
be accessible to the immune system [15]. Antigen screening
Box 1: Reverse Vaccinology Drives the Discovery of New Protein Functions
Reverse vaccinology involves the in silico screening of the
entire genome of a pathogen to find genes that encode
proteins with the attributes of good vaccine targets, using
either the genome of a single pathogenic isolate or the pan-
genome (the genomic information from several isolates) of a
pathogenic species.
Pili in pathogenic streptococci play a key role in
virulence and are promising vaccine candidates The
identification of pili (long filamentous structures that extend
from the bacterial surface) in the main pathogenic strains of
streptococci is a good example of how genomics can lead to
the discovery of protein functions and increased
understanding of host–pathogen interactions. The pili of
gram-negative bacteria are well-described virulence factors.
Little was known, however, about pili in gram-positive
bacteria before the sequencing and analysis of the genomes
of S. pyogenes, S. agalactiae, and S. pneumoniae (reviewed in
[72]).
During analysis of eight S. agalactiae genome sequences,
three protective antigens identified by pan-genomic reverse
vaccinology [20] were found to contain LPXTG motifs typical
of cell wall-anchored proteins and seen to assemble into pili
[73]. Further bioinformatics analysis revealed three indepen-
dent loci that encode structurally distinct pilus types, each of
which contains two surface-exposed antigens capable of
eliciting protective immunity in mice [75]. Because of the
limited variability of S. agalactiae pili, it has been suggested
that a combination of only three pilin subunits could lead to
broad protective immunity [74].
Following the identification of S. agalactiae pili, typical pilus
regions were identified in the available S. pyogenes genomes
based on the presence of genes encoding LPXTG-containing
proteins. In addition, a combination of recombinant pilus
proteins was shown to confer protection in mice against
mucosal challenge with virulent S. pyogenes isolates [75].
Falugi and colleagues have since found that S. pyogenes pili
are encoded by nine different gene clusters, and they
estimate that a vaccine comprising a combination of 12
backbone variants could provide protection against over
90% of circulating S. pyogenes strains [76].
The availability of multiple complete genome sequences for
S. pneumoniae, and the increased understanding of pilus
proteins in other pathogenic streptococci, led to the
discovery of two pilus ‘‘islands’’ that encode proteins that
play a role in adherence to lung epithelial cells and
colonization in a murine model of infection, where they
elicit host inflammatory responses [77,78]. In addition, the
pilus subunits confer protection in passive and active
immunization models [79]. The presence of pili that contain
protective antigens in all three principal streptococcal
pathogens indicates that these structures play an important
role in virulence.
Reverse vaccinology leads to identification of the
fHBP and its role in meningococcal species specificity
Serogroup B N. meningitidis (MenB) strains are responsible
for the majority of meningococcal disease in the developed
world, yet there is no comprehensive MenB vaccine
available. Screening of the MenB genome for vaccine
candidates by using reverse vaccinology led to the
discovery of the meningococcal factor H-binding protein
(fHBP) [15], which was recently suggested to play an
important role in the species specificity of N. meningitidis
[80]. fHBP is a component of the Novartis multivalent MenB
vaccine that entered Phase III clinical testing in 2008 [16,17]
and is also under investigation by Wyeth Vaccines
(designated LP2086) [81] and other groups [82]. Initially
identified as the genome-derived Neisseria antigen 1870
(GNA1870), a Neisseria-specific putative surface lipoprotein
of unknown function, fHBP was renamed because of its
ability to bind complement factor H (fH), a molecule that
down-regulates activation of the complement alternative
pathway. Hence, binding of fH to the surface of Neisseria
allows the pathogen to evade complement-mediated killing
by the innate immune system [83]. fHBP is expressed by all N.
meningitidis strains studied [84]. It induces high levels of
bactericidal antibodies in mice [16] and is important for
survival of bacteria in human serum and blood [83,85,86].
The discovery that binding of fH to N. meningitidis is specific
for human fH, and that human fH alone is able to down-
regulate complement activation and bactericidal activity
leading to increased bacterial survival has significant
implications for the study of this organism [80]. The
administration of human fH to infant rats challenged with
MenB led to a greater than 10-fold increase in survival of
bacteria [80], providing an important insight into host–
pathogen interactions that may lead to the development of
new animal models of infection.
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expressedinEscherichia coliasrecombinantproteins(350 candidates);
confirmation by ELISA and flow cytometry that the antigen is
exposed on the cell surface (91 candidates); the ability of induced
antibodies to elicit killing, as measured by serum bactericidal assay
and/or passive protection in infant rat assays (28 candidates); and
screening of a panel of diverse meningococcal isolates to determine
whether the antigens are conserved. This approach resulted in the
development of a multi-component recombinant MenB vaccine
that entered Phase III clinical trials in 2008 [16,17].
As multiple genome sequences become available for a single
species, the concept of pan-genomic reverse vaccinology is
Table 1. Approaches to identify vaccine and/or drug targets against EIDs in the genomic era.
Approach Methods Used Limitations of Method Example
Organism Disease
Genomics/reverse vaccinology:
Analysis of the genetic material of
an organism in order to identify the
repertoire of protein antigens/drug
targets the organism has the potential
to express.
Bioinformatics screening of the genome
sequence to identify ORFs predicted to
be exposed on the surface of the
pathogen or secreted, expression of
recombinant proteins, generation of
antibodies in mice to confirm surface
exposure, and bactericidal activity [14].
Prediction algorithms need to be
validated.
Non-protein antigens including
polysaccharides or glycolipids, and
post-translational modifications
cannot be identified.
High-throughput cloning and protein
expression is required.
Serogroup B N.
meningitidis [15,16]
Major cause of
septicemia and
meningitis in the
developed world.
Pan-genomics: Analysis of the genetic
material of several organisms of a single
species to identify conserved antigens/
targets and ensure the chosen target
covers the diversity of the organism.
Similar to above, but ORFs are chosen
by screening of multiple genomes with
either direct sequencing or comparative
genome hybridization [18].
Sequences of multiple isolates
of a species are required.
Similar limitations as described
above.
S. agalactiae [20] Leading cause of
neonatal bacterial
sepsis, pneumonia,
and meningitis in
the US and Europe.
Comparative genomics: Analysis of
the genetic material of several individuals
of a single species, to identify antigens/
targets that are present in pathogenic
strains but absent in commensal strains,
and thus important for disease.
Similar to pangenomics, but ORFs are
chosen by screening of genomes from
multiple strains of pathogenic and
commensal strains of a species [18,21].
Similar limitations as for the above
two approaches.
E. coli [22] Major cause of mild
to severe diarrhea,
hemolytic-uremic
syndrome, and
urinary tract infections.
Transcriptomics: Analysis of the set
of RNA transcripts expressed by an
organism under a specified condition.
Gene expression is evaluated in vitro or
in vivo using DNA microarrays or cDNA
sequencing [24].
There is no direct correlation
between the levels of mRNA
and protein.
In vivo studies require relatively
large amounts of mRNA.
V. cholerae [26] Causes diseases
ranging from self-
limiting to severe,
life-threatening
diarrhea, wound
infections, and sepsis.
Functional genomics: Analysis of the
role of genes and proteins in order to
identify genes required for survival
under specific conditions.
Genes that are functionally essential in
specific conditions in vitro or in vivo are
determined by gene inhibition followed
by screening of mutants in animal models
or cell culture to identify attenuated
clones [87].
Genetic tools, acceptance of
transposons, and natural
competence of the pathogen
are required.
H. pylori [32] Major cause of
duodenal and gastric
ulcers and stomach
cancer as a result
of chronic low-level
inflammation of the
stomach lining.
Proteomics: Analysis of the set of
proteins expressed by an organism
under a specified condition and/or in
specific cellular locations (e.g., on the
cell surface).
2D-PAGE, MS, and chromatographic
techniques to identify proteins from
whole cells, fractionated samples, or
the cell surface [34].
Proteins with low abundance
and/or solubility and proteins
that are only expressed in vivo
may not be identified.
S. pyogenes [36] Cause of a range of
diseases from mild
pharyngitis to severe
toxic shock syndrome,
necrotizing fasciitis,
and rheumatic fever.
Immunomics: Analysis of the subset
of proteins/epitopes that interact with
the host immune system.
Analysis of seroreactive proteins, using
2D-PAGE, phage display libraries, or
protein microarrays, probed with host
sera [38].
Bioinformatics prediction of B cell and
Tc e l le p i t o p e s[ 3 7 ] .
Potential bias against sequences
that cannot be displayed.
Large conformational epitopes
made up of noncontiguous amino
acids may not be detected.
Prediction of B cell epitopes is
difficult due to the need to
identify conformational epitopes.
S. aureus [39] Cause of wound
infections. Has
emerged as a
significant
opportunistic
pathogen due to
antibiotic resistance.
Structural genomics: Analysis of the
three-dimensional structure of an
organism’s proteins and how they
interact with antibodies or therapeutics.
NMR or crystallography to determine
the structure of proteins in the
presence/absence of antibodies or
therapeutics [51].
Poor understanding of
determinants of immunogenicity,
immunodominance, and structure-
function relationships.
HIV [53] Causative agent of
AIDS.
Vaccinomics/immunogenetics
pharmacogenetics: Analysis of how
the human immune system responds
to a vaccine or drug.
Investigation of genetic heterogeneity/
polymorphisms in the host, at the
individual or population level, that may
alter immune responses to vaccines [68]
or metabolism of therapeutics [71].
Ethical issues of ‘‘personalized’’
medicine.
Immense diversity of the human
genome and, in particular, in the
human immune response.
Mumps virus [69] Cause of disease
ranging from self-
limiting parotid
inflammation to
epididymo-orchitis,
meningitis, and
encephalitis.
doi:10.1371/journal.pgen.1000612.t001
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antigenically diverse species [18]. Pan-genomics aims to identify
the full complement of genes in a species, based on the superset of
genes in several strains of the same species. Analysis of the genome
sequences of eight Streptococcus agalactiae (also known as group B
streptococcus) strains revealed substantial genetic heterogeneity
and the extended gene repertoire of the species [19]. Screening
found a total of 589 genes predicted to encode surface-exposed or
secreted proteins in the S. agalactiae pan-genome (396 from the
‘‘core genome’’—genes conserved in all strains—and 193 from the
‘‘dispensable genome’’—genes that are present in two or more
strains and are hence considered dispensable for survival). Based
on further screening of this pool of candidates, including the ability
of recombinant proteins to provide protection when used to
immunize animals, a combination of four antigens—only one of
which is in the core genome—was selected and shown to confer
protection against a panel of S. agalactiae strains [20].
Whereas genome sequencing projects have typically focused on
pathogenic organisms, comparison of the genomes of pathogenic and
nonpathogenic strains allows vaccine and drug targets to be identified
on the basis of proteins that are specifically involved in pathogenesis
[21]. Comparative studies of up to 17 commensal and pathogenic E.
coli genomes identified genes unique to certain pathogenic strains that
are largely absent in commensal strains. This filter decreases the pool of
targets to be screened and potentially limits any detrimental effects of
therapeutics on the composition of the commensal flora [22].
New sequencing technologies will also open up opportunities for
monitoring pathogen vaccine escape by screening for evidence of
immune selection in the genomes of pathogen populations before
and after vaccine selection. By deep-sequencing of bacterial and
viral populations it will be possible to identify antigens under
immune selection by monitoring the clustering of single nucleotide
polymorphisms (SNPs) and other mutations that affect protein
sequence. This approach has already been used to search for
evidence of antigenic variation/selection in populations of
Salmonella enterica serovar Typhi [23], where variation is extremely
limited. Similar sequencing strategies could be applied to
populations of bacteria taken before or after a vaccine trial in a
particular geographical region.
Beyond Genomics: Other -Omics Approaches to
Study Pathogens
Pathogen genes that are up-regulated during infection and/or
essential for microorganism survival or pathogenesis can be
identified by using transcriptomics, i.e., the analysis of a near
complete set of RNA transcripts expressed by the pathogen under
a specified condition. Comprehensive DNA-based microarray
chips (probed with cDNA generated from RNA by reverse
transcription) [24] and ultra-high-throughput sequencing technol-
ogies that allow rapid sequencing and direct quantification of
cDNA [25] enable the transcriptome of a pathogen to be
characterized and particular types of gene product to be identified.
For example, genes involved in the hyperinfectious state of Vibrio
cholerae, which appears after passage through the human
gastrointestinal tract, were identified through a comparison of
the transcriptome of bacteria isolated directly from stool samples
of cholera patients with that of V. cholerae grown in vitro [26].
Similarly, analysis of the transcription profile of M. tuberculosis
during early infection in immune-competent (BALB/c) and severe
combined immunodeficient (SCID) mice revealed a set of 67 genes
activated exclusively in response to the host immune system [27].
Functional genomics—linking genotype, through transcrip-
tomics and proteomics, to phenotype—has been applied to many
pathogens to identify genes essential to survival or virulence that
may be valid vaccine candidates. DNA microarrays can be used to
screen comprehensive libraries of pathogen mutants, by compar-
ing bacterial isolates from before and after passage through animal
models or exposure to compound libraries to identify attenuated
clones [28–30]. For example, these methods have been used to
identify 65 novel MenB genes that are required for the pathogen to
cause septicemia in infant rats [31], 47 genes essential for H. pylori
gastric colonization of the gerbil [32], and genes contributing to
M. tuberculosis persistence in the host [33].
Analysis of a pathogen’s proteome (the near complete set of
proteins expressed under a specified condition) to reveal potential
vaccine and drug candidates can add significant value to in silico
approaches [34]. High-throughput proteomic analyses can be
performed by using mass spectrometry (MS), chromatographic
techniques, and protein microarrays [35]. A novel proteome-based
approach has been applied to identify the surface proteins of GAS
by making use of proteolytic enzymes to ‘‘shave’’ the bacterial
surface, releasing exposed proteins and partially exposed peptides.
Seventeen surface proteins of a virulent GAS strain were identified
in this way by using MS and genome sequence analysis. Their
location on the pathogen surface was confirmed by flow
cytometry, and one of them provided protective immunity in a
mouse model of the disease [36].
The proteome of a pathogen can also be screened to identify the
immunome (the near complete set of pathogen proteins or
epitopes that interact with the host immune system) using in vitro
or in silico techniques [37,38]. In vitro identification and screening
of the immunome are based on the idea that antibodies present in
serum from a host, which has been exposed to a pathogen,
represent a molecular ‘‘imprint’’ of the pathogen’s immunogenic
proteins and can be used to identify vaccine candidates. As such,
several techniques have been developed to allow the high-
throughput display of pathogen proteins, and the subsequent
screening for proteins that interact with antibodies in sera.
Immunogenic surface proteins of several organisms have been
identified, including S. aureus using 2D-PAGE, membrane blotting,
and MS [39]; S. agalactiae, S. pyogenes, and Streptococcus pneumoniae
using phage- or E. coli-based comprehensive genomic peptide
expression libraries [38,40]; and Francisella tularensis (the causative
agent of tularemia or rabbit fever) [41] and V. cholerae using protein
microarray chips [42]. Protein microarrays, in which proteins
from the pathogen are spotted onto a microarray chip, can also
be used to characterize protein–drug interactions, as well as
other protein–protein, protein–nucleic acid, ligand–receptor, and
enzyme–substrate interactions [43].
The ability to predict in silico which pathogen epitopes will be
recognized by B cells or T cells has greatly improved in recent
years [44]. Large-scale screening of pathogens including HIV,
Bacillus anthracis, M. tuberculosis, F. tularensis, Yersinia pestis (the
causative agent of bubonic plague), flaviviruses, and influenza for
B cell and T cell epitopes is currently underway [45,46]. Although
epitope prediction is not foolproof, it can serve as a guide for
further biological evaluation. T cell epitopes are presented by
MHC/HLA proteins on the surface of antigen-presenting cells,
which vary considerably between hosts, complicating the task of
functional epitope prediction. Additionally, B cell epitopes can be
both linear and conformational. The ultimate aim of researchers
in this field of study would be to engineer a single peptide that
represents defined epitope combinations from a protein or
organism, enabling the genetic variability of both pathogen and
host to be overcome [44].
Structural genomics—the study of the three-dimensional
structures of the proteins produced by a species—is increasingly
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explosion of genome and proteome data, and continuing
improvements in the fields of protein expression, purification,
and structural determination [47]. The structure-based design of
antiviral therapeutics has led to the development of drugs directed
at the active sites of the HIV-1 protease [48] and influenza
neuraminidase [49]. More than 45,000 high-resolution protein
structures are available in public databases (see http://www.
wwpdb.org/stats.html), and several initiatives have been estab-
lished to pursue high-throughput characterization of protein
structures on a genome-wide scale [50], focusing on determining
and understanding the structural basis of immune-dominant and
immune-recessive antigens as well as protein active sites and
potential drug-binding sites [51,52]. For example, structural
characterization of the HIV envelope proteins gp120 and gp41
has revealed mechanisms used by the virus to evade host antibody
responses, many of which involve hypervariability in immunodo-
minant epitopes [53,54]. Based on this information, immune
refocusing (e.g., by retargeted glycosylation, deletion, and/or
substitution of amino acids) has been used to dampen the response
to variable immunodominant epitopes of the envelope glycopro-
tein gp160, enabling the host to respond to previously subdom-
inant epitopes [55]. High-throughput modification of proteins and
their screening for immunogenicity and interaction with antimi-
crobials is predicted to become more common as techniques
evolve [51].
The Contribution of Human Genomics
When designing new vaccines, one important consideration is
the risk that the vaccine might generate ‘‘self’’ immune reactions
against host epitopes; immune responses against a pathogen
antigen can cross-react with host antigens if homologies exist in the
primary amino acid sequence or structure, potentially leading to
damage to the host tissue [56]. Drugs aimed at pathogen targets
could also theoretically target similar host molecules. The
availability of the human genome sequence combined with
methods for predicting B cell and T cell epitopes will facilitate
screening for the presence of homologies between candidate
microbial vaccine antigens and proteins in humans, enabling issues
of autoimmunity and cross-reactivity to be tackled [57]. As such,
vaccine or drug targets identified using methods based on
pathogen genomics should be screened for homology or similarity
to human proteins in silico, using programs such as BLAST (Basic
Local Alignment Search Tool; http://blast.ncbi.nlm.nih.gov/
Blast.cgi) to query human genome databases. Interestingly,
analysis of 30 viral genomes revealed that around 90% of viral
pentapeptides, which could be components of epitopes, are
identical to human peptides [58]. There is little homology,
however, between validated immunogenic disease-associated
peptides/epitopes and host peptides [57,59], suggesting that
screening approaches that include prediction of immunogenicity
could improve the pool of target candidates.
It is important to keep in mind that we do not fully understand
how self-tolerance is broken, so we currently have no perfect way
of predicting all potential autoimmune triggers that could be
associated with vaccination. While many links have been made
between autoimmune disease and vaccination, they have been
confirmed in only a small number of cases (reviewed in [60]). For
example, treatment-resistant Lyme arthritis is associated in certain
patients with immune reactivity to the outer surface protein A
(OspA) of the causative agent of Lyme disease, Borrelia burgdorferi,
and an OspA epitope (OspA165–173) has homology to the human
lymphocyte function-associated antigen (hLFA)-1aL [61]. As a
result, the OspA-based Lyme disease vaccine (LYMErix) was taken
off the market in 2002, but a recombinant OspA lacking the
potentially autoreactive T cell epitope has been proposed as a
replacement vaccine [62].
Rather than targeting drugs to pathogen enzymes, an
alternative approach has focused on targeting the host-cell proteins
that are exploited by pathogens for replication and survival. The
use of techniques including microarray-based analysis of virus-
induced host gene expression has revealed several possible targets
[63,64]. The cholesterol-lowering drugs statins, for example, have
an anti-HIV effect that is believed to be mediated by preventing
activation of the host protein Rho, which is activated by the HIV
envelope protein and required for virus entry to the cell [65].
Furthermore, such studies can improve our understanding of the
host immune responses that protect against a pathogen (i.e.,
innate, antibody, Th1, or Th2 responses), which will aid the
selection of appropriate vaccine adjuvants. For example, induction
of interferon signaling early in infection may be critical to confer
protection against SARS-CoV, as determined from functional
genomic studies of early host responses to SARS-CoV infection in
the lungs of macaques [66].
Many of the genes of the human immune system are highly
polymorphic, which enables the population as a whole to generate
sufficient immunological diversity to combat EIDs. This variation
also impacts on the outcome of vaccination and treatment. The
International HapMap Project has identified over 3.1 million
SNPs in 270 individuals [67] and the 1000 Genomes Project aims
to identify even more genetic variants. The field of vaccinomics
(also called immunogenetics) investigates heterogeneity in host
genetic markers that results in variations in vaccine-induced
immune responses, with the aim of predicting and minimizing
vaccine failures or adverse events [68]. For example, polymor-
phisms of HLA and immunoregulatory cytokine receptor genes
are associated with variable outcomes of vaccination against
mumps [69]. Similarly, pharmacogenetics, which investigates
genetic differences in the way individuals metabolize therapeutics,
has found that human variability in the speed of metabolism of the
common first-line tuberculosis drug isoniazid is associated with
genetic variants, including SNPs, in the gene encoding arylamine
N-acetyltransferase (NAT2) [70,71]. The ability to predict an
individual’s response to a vaccine or drug, may eventually allow
physicians to determine whether a patient is genetically susceptible
to a disease, the possible adverse effects of a vaccine or drug, and
the appropriate schedule or dose to use.
Challenges for the Future
We predict that genomics will greatly aid the control of EIDs
because of the increased efficiency with which vaccine and
therapeutic targets can be identified using the genome-based
approaches described above. Furthermore, we anticipate the
continual refinement and development of novel genome-based
approaches as sequencing becomes faster and more affordable.
Several challenges remain, however, in the identification of these
targets and in the processes needed to bring a new vaccine or drug
to the market. Understanding the molecular nature of epitopes,
the mechanisms of action of adjuvants, and T cell and mucosal
immunity are key priorities to be tackled in the coming years [3].
These issues can be addressed by improved structural studies of
antigen epitopes and the compilation of databases containing
information on structure, immunogenicity, and in silico B cell and
T cell epitope predictions. Genome-based development of effective
vaccines and therapeutics is still largely dependent on the
availability of valid models to measure efficacy and protection
PLoS Genetics | www.plosgenetics.org 6 October 2009 | Volume 5 | Issue 10 | e1000612against disease; however, the increased understanding of microbial
pathogenesis that is emerging from genomics should greatly aid in
this respect. Likewise, the continued development of animal
models with knockout and allele-specific mutations in key
components of the immune response will greatly increase
understanding of the type of immune response needed to control
disease and the ways in which the immune system can be
programmed to protect the host against disease. Unfortunately,
the stepwise series of prelicensure clinical trials (Phase I, II, and III)
that are required to document the safety, immunogenicity, and
efficacy of a vaccine are still highly time-consuming and costly. We
can only hope that the increasingly ‘‘smart’’ identification and
design of targets, and the fresh impetuous given to the fields of
vaccine and drug development by the arrival of genomics, will
enable increased success of those vaccines and drugs that do make
it into clinical development.
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